Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fact is, it has been much higher in the past so why shouldn't it get there again? If anything, the social situation now--legalized MJ and Bitcoin--is much more supportive of EFFI's enterprises than back then.
For sure i don't understand what's going on--Just know that if i sell now, at a horrendous loss, that's when the price will recover. So i hold on and hope.
Exactly!
I said all this a long time ago and was beaten up for saying it. But the company has been around for a long time so hopefully it will come back up. A nickel is good enough for me.
Totally agree. $ERBB will be among top MJ leaders. Vertically integrated company. I trusted my intuition, sold a few of my best $stock to buy in to $ERBB yesterday.
Sure i'm down a little bit today but so what? We have to look at the Big Picture and hold on. This is a long-term investment if you are looking for BIG money.
I think $1.00 is highly unrealistic as soon as the end of this year but it could happen eventually. I do believe that ERBB is developing into one of the topmost leaders in the MJ market--which is why i started a large and long position yesterday!
All that's needed to resolve this is a call to Dianne. Let's find out what the actual situation is as of right now.
No RS! On youtube Stephen specifically said during Q/A.
I don't have the link but someone posted it yesterday.
The sooner the buy-out, the longer will be the acquiring company's patent protection. But because PFE has been burned before, big time, the acquiring company probably wants to see FDA approval of the first product before committing. Also will bring in much more $ to ELTP. As has been mentioned, it's gonna happen at the "sweet spot" for both companies.
We are so lucky that NH has so much of his own skin in the game. He is gonna do the right thing for all of us, including himself. We are gonna collect that Pot of Gold at the end of the Rainbow! Go ELTP!
my one post
"There is purpose behind the large outstanding share count."
What does this mean? What good purpose is there for a huge, ginormous share count?
COUCH, LASERS, NASDAQ--please comment on these things (consolidated issues for my one post of the day):
1. "ADT OPIOIDS do not stop addiction but curtail the abuse of opioids".
Not completely correct, imo. ADTs do help to stop addiction in legitimate users of opioids for pain control because ADTs prevent euphoria, so the pain meds patients don't get hooked or certainly much less so.
2. "Nasrat said on July 1 he has gotten calls to do interviews and go on TV shows but he REFUSED to do them even though he ADMITTED it would help". Interviews might help the pps in the immediate timeframe but that just helps traders. If anything, keeping the pps low for awhile is helping longs acquire more shares and helping new investors to start more easily.
3. Furthermore, NH's main concern is helping the company by staying focused on getting those ADTs launched.
4. lowered pps since Rodman =traders taking profits, imo
I didn't mean asking them to update the person writing. I meant them issuing some kind of public update in response to the requests of numerous shareholders. Their ongoing silence for months on end is unreasonable.
Have you written management asking them to update us?
I have several times but no response. Everyone on the board should write them asking them to respond to us and let us know wtf is going on with this company!
http://biz.yahoo.com/e/140908/korx8-k.html
I've read it but i don't understand how it relates to or affects EFFI. If someone else does, please explain.
Most opioid prescriptions are written for legitimate patients seeking pain control, not for addicts.
Obviously wrong and ridiculous to say that the market for opioids will disappear once ELTP's ADT formulations dominate the market (assuming FDA mandates ADT formulations once ELTP's are available and/or assuming that doctors simply choose to prescribe ELTP's ADT formulations, once they are available--both of which assumptions are highly reasonable and likely).
Also obviously wrong and ridiculous to argue that--if most prescriptions are for legitimate pain control--then ADT formulation is not necessary. ADT formulation is necessary to keep non-addicted, legitimate users of pain meds, from becoming addicted. Those who are already addicts will seek out another source of highs (such as heroin) but many people who are not yet addicts will be spared the curse of addiction.
And also it will be a great blessing for pharmacists that their stores will no longer be targeted by addicts and/or dealers as a source to get their opioids!
The FDA and Congress want to stop the surge in opioid drug deaths and they will therefore support the introduction of really good ADT formulated opioids--namely the amazing pipeline of ELTP drugs, soon coming to a pharmacy near you.
With the vast increase in all kinds of surgeries worldwide--including a major increase in cosmetic surgeries--and with the huge increase in elderly people worldwide--(many of them suffering more aches and pains, as well as having more surgeries)--the market for opioid pain medication worldwide is growing by leaps and bounds.
ELTP will be providing exactly what the FDA and Congress and many other governments, doctors, and concerned citizens, are looking for.
HAVE PATIENCE!!! Remember what Warren Buffett says: "The stock market remains an exceptionally efficient mechanism for the transfer of wealth from the impatient to the patient".
My one post for the day.
$ELTP ORDER OF DRUG LAUNCHINGS:
*****************************************
$ELTP NDA filings will be as follows:
$ELTP 1st ADT is ELI-200 Morphine/Naltrexone.
$ELTP 2nd ADT is ELI-202 Hydrocodone/Naltrexone
$ELTP 3rd ADT is ELI-201 Oxycodone/Naltrexone.
The above info was posted by Lasers on Aug 22, 2014
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Firstly ELI-200 (Morphine) and then secondly ELI-202 (Hydrocodone). ELI-201 (Oxycodone 12 Hr ER)will be third and followed by ELI-216 (Oxycodone 24 Hr ER) 4th.
ELI-200 and ELI-202 will dominate opioid sector so that $ELTP can take their time with moving forward with ELI-201 and ELI-216
The above info was posted by Lasers on Sept 8, 2014
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
NEXT FOUR MONTHS
Isradipine 2.5 mg and 5.0 mg capsules Approval
Isradipine 2.5 mg and 5.0 mg capsules Launch
Dantrolene Sodium 25 mg, 50 mg and 100 mg capsules Approval
Dantrolene Sodium 25 mg, 50 mg and 100 mg capsules Launch
Loxapine 5mg, 10mg, 25 mg, 50 mg capsules Approval
Loxapine 5mg, 10mg, 25 mg, 50 mg capsules Launch
Hydroxyzine HCI 10 mg, 25 mg, 50 mg tablets Approval
Hydroxyzine HCI 10 mg, 25 mg, 50 mg tablets Launch
ELI-201 Pivotal BE Results
ELI-202 Pivotal BE Results
ELI-200 In Vitro Lab Abuse Study Results
ELI-200 In Vivo Human Abuse Liability Results
ELI-202 In Vitro Lab Abuse Study Results
ELI-202 In Vivo Human Abuse Liability Results
ELI-203 Pivotal BE Study Initiation
Partnership announcement(s)
November 2014 Conference Call
December ELI-200 NDA ART FDA Filing
Guess i'll have to wait to sell @ buyout or at $9.00 MINIMUM (17 ADTs @ $4 each).
90--99% of opioids will be required to be formulated with ART/ADT and ELTP's modular formulation is the best and works with all opioids.
My one post of the day
Even more important question is WHY???
Obviously Wrong and absurd notion! If someone wanted to unload a lot of shares, they would certainly NOT be trying to hold the price down! On the contrary, they would be trying to keep the PPS UP! That's why they would sell in small increments.
Warren Buffett says: "The stock market remains an exceptionally efficient mechanism for the transfer of wealth from the impatient to the patient".
My one post for the day.
"Hospitals and doctors will finally have a choice. Oxycodone with no ART or oxycodone with ART. Morphine with no ART or morphine with ART. Hydrocodone with no ART or hydrocodone with ART. "
Actually, hospitals and doctors might not have a choice once really good ARTs are available--from $ELTP--because opioids without ART might then become illegal to prescribe except in very rare and unusual cases.
*****$ELTP--ALL THE INFO YOU NEED*****
FIRST--According to ELTP's CFO, Carter Ward:
Revenues are up, product development continues to accelerate, we’re on track for our first opioid filing this year, and financially Elite has never been stronger.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
SHORT SUMMARY OF WHERE ELTP IS AT RIGHT NOW:
2 POSITIVE BE trials already, multiple generics in market, expanded facility, new qualified hires, new production equipment, partnership with Camargo, secured funding in our back pocket, NJ bond debt fulfilled, and a CEO who with over 11 MILLION personal shares of stock and the motivation to bring ART to market......
September:
- Elite participation in the Rodman & Renshaw Global Investment Conference
- Preliminary results from abuse trials
October
- Abuse trial results published
- Additional BE trial results published
December
- NDA submission for opioid product in MULTI-BILLION DOLLAR CATEGORY
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
AMAZING BIO OF OUR CEO, MR. NASRAT HAKIM
Businessweek.com
http://investing.businessweek.com/research/stocks/people/person.asp?personId=35746834&ticker=ELTP
Mr. Nasrat Hakim has been the Chief Executive Officer and President of Elite Pharmaceuticals, Inc. since August 1, 2013. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He has a proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. He served as a Vice President of Quality Compliance and Technical Services at Actavis LLC. Mr. Hakim served as Vice President of Quality of Alexza Pharmaceuticals Inc. since July 18, 2007. Mr. Hakim served as Corporate Vice President of Quality and Compliance for Actavis / Alpharma Inc., and previously served as Global Vice President of Compliance for Alpharma, where he was employed from 2004 to 2007. He has been a Director at Elite Pharmaceuticals, Inc since August 1, 2013. Mr. Hakim has also served as Executive Director of Corporate Compliance and Technical Projects for Watson Pharmaceuticals and Executive Director, Site Head of Quality and Compliance at TheraTech, Inc. Watson Pharmaceuticals acquired TheraTech in 1999. Mr. Hakim holds both a JD and BS in Law from Saratoga University in San Jose, California, a Masters degree (LLM) in Law from St. Thomas University in Miami, Florida and Bachelors and Masters degrees in Chemistry from California State University at Sacramento.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
FABULOUS FACT ABOUT OUR CTO:
The CTO of Elite (ELTP) is also the CEO of EPIC, the largest contract drug manufacturer for large pharma--and he is paid by ELTP in shares.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
LIST OF SOLID ACHIEVEMENTS AND FACTS ABOUT ELTP (compiled by DD long Nasdaq) that all investors should remember and refer to often--especially if any wayward doubts creep into your mind. Perhaps paste it on your refrigerator. There is no speculation here, only solid facts. See for yourself:
--no more going concern, bond debt current
--strongest balance sheet in Elite's history
--first working capital surplus in 5 years
--The Company’s primary focus has become the accelerated development of their complete line of Abuse Resistant opiods
--Elite's goal is to become the leader in the ART/ADT opiod market "no one will stop us" "we are going to market" CEO
--"We have set in motion several initiatives that will have significant impact on Elite's future" CEO
--aggressive schedule with clinical trials, quadrupling of R&D costs, working on *5-6 ART opiods* concurrently in 2014,
one or two ART/ADT opiods will be filed with FDA in 2014 if fast track status granted
--the longer we go without partnering the high the value of the company
--$40 MILLION in funds secured from LPC(Lincoln Park Capital) to develop ADT/ART products with or without a partner
--$5 MILLION more recieved from sale of Elite's 9.99% ownership in Novel Laboratories 06/10/2014
--Multiple potential partners are approaching ELTP and are waiting on trial results. CEO wants to license ART "after studies and trials completed" making it worth much more due to the steep accretion curve in the pharma field ie. the value goes up exponentially as studies are completed
--completed SUCCESSFUL pivotal bioequivalence studies on both ELI-201(twice day oxy ADT) and ELI-200(undisclosed twice a day)
ADT opiod) Abuse studies for ELI-200 underway
--Generic Business Cash Flow Positive minus R&D costs for last two quarters, approaching 2+ million in revenues per quarter
--Poison Pill 8-A12G filed and a staggerd Board of Directors in place protects shareholders from a hostle take over, independent analyst determined the value of Elite is undervalued and its true value is between $2.10 and $2.75 as of late 2013
--Nasrat Hakim, Elite's President and Chief Executive Officer has provided an unsecured line of credit not to exceed $1,000,000. Proceeds will be used to support Elite's acceleration of ART product development activities.
--Board member Jerry Trepple loand $600,000 unsecured took repayment of his loan in preferred I shares
--Billion dollar pipeline-33+ DRUGS including a complete line of 17 NDA and ANDA abuse resistant (ART) opiods plus multiple generics
Compare Q2'13 vs Q2'12 Revenue increased +131%
Compare Q3'13 vs Q3'12 Revenue increased +30%
Compare Q4'13 vs Q4'12 Revenue increased +134%
Compare Q1'14 vs Q1'13 Revenue increased +27%
Compare Q2'14 vs Q2'13 Revenue increased +83%
Compare Q3'14 vs Q3'13 Revenue increased +154%
Q4'14 ended the year off with the BEST year for earnings EVER for ELITE
--20 FDA approved drugs: 8 launched and gaining market share: hydromorphone, phentermine 37.5 mg, lodrane D, methadone, phendimetazine, phentermine 15mg, phentermine 30mg, naltrexone 50mg.
--Elite has signed a Manufacturing and License Agreement with Epic Pharma who will manufacture 11 of the 12 approved generics ANDAs recently obtained from MIKAH. This will allow Elite to maximize their profit potential for their generic business while devoting their resources to the development of their abuse resistant products. Isradipine CBE-30 filed by Elite and will be manufactured by Elite and only has 1 competitor in a 6 million dollar market. EPIC will file CBE-30 for the second MIKAH ANDA Dantrolene in June 2014, it has one competitor in a 12 million dollar market
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
--Partnered with CAMARGO for assistance with 505(b)(2)opportunities for multiple 12 hr ART generic and NDA opiods where Bio-equivalency studies alone are enough
trial #1 mega pilot 4 way cross over on 64 subjects SUCCESSFUL on 12 hr Oxy/Nal ELI-201 completed in 2013
trial #2 and 3 pivotal BE studies SUCCESSFUL for both ELI-201 (12hr oxy) and ELI-200 (12hr undisclosed) ADT
trial #4 and #5 Started 05-19 for ELI-202:the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-202, an undisclosed opioid abuse deterrent product, utilizing Elite's proprietary pharmacological abuse deterrent technology. Two bioequivalence studies will be run together for ELI-202.
2014 Lifetree 3 tier abuse deterrent studies to obtain * FDA ADT LABELING *
a) snorting trial
b) oral abuse
c) IV abuse
Additional Human Abuse Liability Study started June 2014 to test abuse potential of crushed ELI-200 taken intranasally
ELI-200 believed to be morphine/naltrexone(a better Embeda) is also on schedule for a Dec 2014 FDA filing
trial #5 June/July 2014 ONCE/DAY 24 hr ELI-216 ** $$ will eventually be the ONLY 24 hr oxy in the USA $$ **
this one product may need a Phase III trial, FDA to decide after BE's
--ELI-154 CR (once a day Oxy) in scale up for Large European Market
--CEO owns 23% of co. and has challenged team to get the First 12 hr ART Oxycodone filed with the FDA in 2014
The 12 hr product is for a
*******2.7 Billion dollar market*******, CEO commented that a conservative 20% of that market would get us ****$4.00-$5.00 PPS**** with just their first ART opiod
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
--Nasarat Hakim former VP of Activas appointed president and CEO of Elite 08-05-13 has 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. He is making ART priority one. He bought 11 million shares on the open market and takes ELTP stock as compensation. The CEO noted, we are trading on our financials(revenues) and if we had no revenue we would be trading on ART and R&D and we would be valued ***10X*** higher
--Barbara Ellison has been given the position of VP Quality Control Operations & Regulatory Affairs: Barbara will oversee the regulatory and quality functions for Elite and will play a key role for the Company as it expands the product development and commercialization of the Company's opioid abuse deterrent products. Her role was created to support the abuse deterrent product filings, the first of which is planned for THIS year. She also be an important contributor as Elite files additional products and launches our first abuse deterrent product. Her national and international expertise in quality management and regulatory affairs will richly support Elite's compliance and quality goals.
--FDA likes the pharmalogical approach to abuse resistance FDA being very positive
--the ART is rock solid, innovative, superior and he has not seen a better ART CEO
--1st patent for 2 bead ART 8/182,836 abuse resistant oral formulations and method of use thereof (approved May 22, 2012) method for making an abuse resistant drug
--2nd patent for 2 bead ART 8/425.933 formerly 12/640,344 (04/23/2013) combined with first patent, gives Elite 20 years of propietary protection: formulation to make an existing drug abuse resistant
--3rd ART Hammerlock patent 8,703,186 April 2014
--**Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof”. Issuance 03/2014 expands the scope and reach of Elite’s patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe.
--Additional European and Canadian Patents Pending
--Elites ART is modular, it can be used on ALL opiods just add a different opiod bead to the naltrexone bead
--NE 30 polymer for sequestering naltrexone was found to be far superior to other polymers
--Elite may license these ART products at a later date to a third party who could provide funding for the remaining clinical studies and who could provide sales and distribution for the product.
--Patent pending 13/379,481 microtablets for use with Elite's abuse resistant products
--Patent pending 13/379,486 microtablets 0.25-1.0mm, smallest in the industry for use with ALL medicines
--patent 12/075,816 for Sequestering polymer acrylic co-polymer composition: ON HOLD while Elite and lawyers Woodcock & Baker strategize to add more claims
***The recent guidances and actions by the FDA related to extended release opioids and specifically oxycodone demonstrates the FDA support for abuse resistant technologies
Opioid products incorporating abuse resistant technologies have become a public health priority and these recent actions appear to be a major step towards the FDA eventually requiring that all extended release opioids utilize these technologies.
January 9, 2013, the FDA released its new draft guidance document, titled "Guidance for Industry: Abuse-Deterrent Opioids - Evaluation and Labeling". The document discusses what it will take for an opioid formulation to secure an abuse resistant label. The implications for companies that meet these expectations are significant and even more so for those that meet these requirements and have patented abuse resistant technologies.
March 2013, 48 state attorney generals called on the agency to require generic makers to produce tamper-resistant versions of opioid medicines
--the STOPP ACT - a bill before Congress NOW, introduced by US Rep's Rahall, Rogers and Keating. The law will prohibit any old-formula opiod from entering the market if the FDA has an equivalent abuse deterrent/resistant opiod approved
--CLADD petitions FDA to reject all opiods without ART
--FDA's Purdue ruling April 16, 2013 : prohibits new original non-abuse resistant oxycodone from being made in generic form, unless it has an abuse deterrent/resistant properties. FDA will not accept or approve any ANDA applications based on the original OxyContin formulation
--the FDA decision basically requires generic companies to buy or develop their own abuse deterrent/resistant technology: it effectively eliminates much of Elite's competition which has no ART thus making Elite's 2-bead ART MORE VALUABLE
--going foward all new generic and probably NDA branded opiods will be required to have Abuse deterrent/resistant properties
--May 10, 2013 Endo Health (ENDP) ruling
--Elite's Competition being taken out one by one by the FDA and later the US Congress
--2-bead abuse resistant opiods could gradually replace some of the inferior abuse deterrent opiods now on the market
--CEO and officers being paid with stock
--multiple partners Watson/Actavis, Mikah, Epic, TAGI, The Pharm Network, ECR, Precision Dose, Celgene Corp, TPN/Ascend, Novartis, SmithGlaxoKlein and the undisclosed Hong Kong Pharma
--contracting deals with other pharmas
--TWO 15,000 sq/ft FDA-DEA-cGMP registered manufacturing labs for research, development and manufacturing from concept to commercialization $500,000 invested in faclity in 2014, new encapsulator, tablet press and high shear grandulator
--NEW packaging line operational
--39 employees over double of two years ago
--CEO wants to get a $50 million/ yr ANDA per shareholder meeting 2014
--phentermine 15 & 30mg launched (April 11, 2013) is competing with Qsymia(phentermine and topiramate)
--Acend Labs has new contracts for methadone
--Hong Kong Pharma NDA development over a year to go
--MIK-001 505b2 NDA maybe an improved Embeda on schedule in development on the back burner
--HITK's intermediate for a generic of a branded 100 million dollar market= drug Lots produced
--Naltrexone 50mg launched Sept 2013
--Lodrane 24D equivalent waiting on feed back from FDA they will tell them which pseudoephedrine salt to use and which product to use to run trials with
--undisclosed 100% Elite owned ANDA approx 1 year
--Elite's goal is to commercialize a COMPLETE LINE of 17 abuse resistant opiods
--Uplisting to the NASDAQ exchange per the CEO
--ELTP visibility increasing: Once the pilot and pivotal studies completed in March 2014 CEO to go on the road to present the results to viable partners
--Elite will be attending Rodman Renshaw conference again in Sept 2014
http://seekingalpha.com/article/1688112-elite-pharmaceuticals-call-it-a-comeback-story?source=yahoo
http://seekingalpha.com/article/1905051-elite-pharmaceuticals-swingfor-the-fences
http://seekingalpha.com/instablog/4199131-couch/1941422-elite-pharmaceuticals-eltp-intellectual-property-ip-and-the-right-to-devise-a-better-pain-killer
--500 series I convertible stocks created (02/07/14) with a value of 50 million dollars. 105 were used to pay off CEO's drug transfer and Trepple's unsecured loans, 395 available IF NEEDED at a to be determined share conversion price, these can also be used for financing and leverage for a favorable deal for shareholers
--Partner Camargo is a full-service drug development partner specializing in the 505(b)(2) process — an approach for developing products that offer differentiated benefits. Camargo is capable of managing every facet of the plan throughout the development continuum, from feasibility assessments, formulation and testing the drug product, to conducting preclinical and clinical studies, to final submission
--Important FDA meeting coming up in August 2014
"We have emerged as one of the leaders in the development of abuse deterrent opioids"
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
WHAT TO EXPECT IN THE NEXT 4 MONTHS:
Rodman & Renshaw Conference
Isradipine 2.5 mg and 5.0 mg capsules Approval
Isradipine 2.5 mg and 5.0 mg capsules Launch
Dantrolene Sodium 25 mg, 50 mg and 100 mg capsules Approval
Dantrolene Sodium 25 mg, 50 mg and 100 mg capsules Launch
Loxapine 5mg, 10mg, 25 mg, 50 mg capsules Approval
Loxapine 5mg, 10mg, 25 mg, 50 mg capsules Launch
Hydroxyzine HCI 10 mg, 25 mg, 50 mg tablets Approval
Hydroxyzine HCI 10 mg, 25 mg, 50 mg tablets Launch
ELI-201 Pivotal BE Results
ELI-202 Pivotal BE Results
ELI-200 In Vitro Lab Abuse Study Results
ELI-200 In Vivo Human Abuse Liability Results
ELI-202 In Vitro Lab Abuse Study Results
ELI-202 In Vivo Human Abuse Liability Results
ELI-203 Pivotal BE Study Initiation
Partnership announcement(s)
November 2014 Conference Call
December ELI-200 NDA ART FDA Filing
~~~~~~~~~~~~~~~~
When you buy shares of ELTP, you are buying into a Great COMPANY, NOT an ever-shifting pps! If you focus on all the great things the COMPANY has going for it (instead of the heavily manipulated pps), you will know that you're in the right place at the right time.
Of course it's a Real Possibility! Tiny niche pharmaceuticals are constantly being bought up by Big Pharma at high prices. Saves BP the trouble and expense of doing all the tiresome groundwork themselves and gives them a whole new line of drugs for $$$$$$$$!
Regarding the "lame" lack of communication from management, i agree it is extremely frustrating.
However, the people who are upset with management need to tell them instead of just complaining to us. Unfortunately, we can't do anything (except ask, beg and plead to management that they tell us something).
So, whatever you are complaining to us about, please also tell management. I have done so several times. So far, it has brought no results but maybe if more people call and/or write them, they will get the message.
When you buy shares of ELTP, you are buying into a Great COMPANY, NOT an ever-shifting pps! If you focus on all the great things the COMPANY has going for it (instead of the heavily manipulated pps), you will know that you're in the right place at the right time.
If you relax and go do something else besides staring at the pps all day, one of these days in the not-too-distant future, you will be well rewarded!
"Let us all now pray"...
ELTP is the Real Deal! Read Lasers' posts about Targiniq misleading advertising. He explains how this is actually not a pain relief drug but is geared only to relieve opioid-induced constipation (OIC), the constipation that is induced by opiate drugs.
One of Lasers' posts says:
"The FDA approval of Mundipharma’s 8-yr old anti-OIC co-drug oxycodone-naltrexone Targin®, Targiniq®, and Targinact®, for Purdue as an ART opioid reeks sky high. Further, approval as an ADT is sure mockery to the rest of the Pharmaceutical Industry. No responsible Medical Doctor would ever prescribe this drug other than for anti-OIC".
Accumulation (buying) is made possible only by equal amounts of selling, right? So who is selling and why? Is it just MMs doing what they are actually supposed to be doing? (i.e. facilitating a market) or what?
It seems crazy for anyone to be selling just before R+R and all the great stuff we have every reason to expect is coming over the next few months! Can someone please explain? Thanks in advance.
ELTP up 295.88% for the year!!!
PFE up 4.34% for the year
ok, need some GOOD news here! But is there any???
Bitcoins may be gaining acceptance.
http://dealbook.nytimes.com/2014/08/25/on-to-do-list-deposit-cash-in-bitcoin-a-t-m/
Will that help effi? Will *something* help effi???
Some pretty weird things i've noticed trying to get more info on the company: Their website still lists Shawn Clinton as their CEO, who resigned months ago, and doesn't even mention the new CEO Mr. Alexander Desousa.
As to the numerous accounts of Mary-Kathryn (MK) Tantum--supposedly the new CTO--they don't mention EFFI at all, only her other companies. Here is her latest posting on her twitter account:
MK Tantum @mktantum · Aug 22
...and we're off to Cuba! Yes, that's a bike. This should be interesting. :) So long, Internets...I shall miss... http://fb.me/20ZWVQYLJ
What could be the meaning of all this?
Please explain the connection to EFFI. thanks.
Does tight spread indicate something good for the pps?
'LASERS': is ADT ELI202 Hydrocodone/Naltrexone NDA the first ADT that ELTP is filing for (by end of 2014)?
NH would not sell for $2.00!!! Probably not even for $5.00. $10??? Maybe but doubtful, imo.
Bitcoin’s Price Falls 12%, to Lowest Value Since May
By SYDNEY EMBER AUGUST 18, 2014 3:35 NY Times
On Monday, the price of Bitcoin dropped nearly 12 percent, to $435.60 from $492.95, according to the virtual currency website CoinDesk, its lowest value since May and far below its peak of about $1,150 last year.
Also on Monday, the price briefly plummeted to $309 on BTC-e, an exchange with shadowy backing, in what some in the industry called Bitcoin’s version of a “flash crash.” That collapse, however, was short-lived, and the price quickly recovered to where it was trading before. The virtual currency also regained some of its lost ground to return to trading around $460 late Monday.
Photo
Credit The New York Times
Yet, despite the latest one-day swing, Bitcoin’s price has been steadily falling in recent weeks, a trend that follows a period of relative stability since February when the Bitcoin exchange Mt. Gox collapsed.
It also is occurring as new regulations and a general stock market malaise have taken hold.
In July, New York became the first state to propose regulations for virtual currency companies. The regulations, introduced by the Department of Financial Services, include rules on consumer protection, the prevention of money laundering and cybersecurity. A “BitLicense” would be required for Bitcoin exchanges and for companies that secure, store or maintain custody or control of the virtual currency on behalf of customers, which some supporters fear is much too broad.
Last week, another regulatory agency, the federal Consumer Financial Protection Bureau, issued a warning on virtual currency, further igniting fear in the Bitcoin world over possible restrictions.
“Over all, the sense is that regulation is going to impede the growth of Bitcoin, which is contributing the negative sentiment,” said Gil Luria, an analyst at Wedbush Securities. “What’s been weighing on Bitcoin more are shorter-term concerns about whether Bitcoin can develop.”
Those who are familiar with the virtual currency sector shrugged off the latest price movement, which they said was well within the typical range for the currency.
“This is just how Bitcoin trades, for better or worse,” said Barry E. Silbert, who oversees a Bitcoin investment fund through his company, SecondMarket. “This is normal — par for the course.”
Bitcoin’s wild price swings, however, can be jarring, particularly for those who are new to virtual currency. Since Bitcoin was introduced in 2009, its value has gone from just a few dollars to more than $1,000. On any day, the currency’s price can fluctuate by more than 5 percent.
What makes the recent decline notable is the relative calm that preceded it. The price has hovered around $600 since June and has not fallen below $500 since May, according to CoinDesk.
Credit
“What was surprising in some ways was the period when Bitcoin was trading around $600 and not losing much price,” said Steven Englander, a research analyst with Citigroup. “The stability probably means that there isn’t much going on.”
Bitcoin is not the only alternative currency to decline in recent days. So-called altcoins — including Litecoin, which has the second-highest market capitalization behind Bitcoin — have fallen in value across the board, according to the website CoinMarketCap.
Analysts and seasoned Bitcoin supporters may not be concerned about the recent dive, but the volatility is probably not helping push the currency into the mainstream, analysts said. Unlike investors, who often bet on such price swings, more casual users are less likely to adopt a currency with such an unpredictable value.
“The range of fluctuations in Bitcoin has a dampening effect on consumer enthusiasm,” Mr. Luria said.
This could spell trouble for the growing list of merchants, including Overstock and Dell, that have started accepting Bitcoin as a payment option. Retailers are immune to Bitcoin’s volatility because they accept the currency through a third-party payment processor, which immediately converts it to dollars. Consumers who transact in Bitcoin, however, must hold some of the currency, making them susceptible to any price change.
Since Bitcoin was introduced in 2009 by a programmer, or group of programmers, it has become increasingly more popular, particularly among investment companies and entrepreneurs. But consumers have remained reluctant to embrace the currency, partly because of its unpredictable price.
And analysts and investors, for the most part, do not expect this volatility to end soon. They cite the wide range of possible outcomes for the currency, so any small change in perception can drive a big price swing. In 10 years, for example, one Bitcoin could be worth millions of dollars if it becomes the global capital of trade. But it could also be worth next to nothing if its development is stanched by strict oversight.
“It’s very hard to come up with a fundamental value for Bitcoin,” said Mr. Englander, the Citigroup analyst. “What really defines the price is its reputation and expectations for the future.
To everyone who complains that such-and-such wasn't mentioned in the CC/or "the silence was deafening"/or "was hoping for" whatever info: why didn't you get on the phone and *ask* for this info???
Pfizer should just buy out ELTP! That would solve everyone's problems real quick!
Ever heard of delays beyond one's control in the biotech field??? If you want something that goes like Swiss clockwork, invest in a CD.
**** Elite Pharmaceuticals Conference Call Questions ****
Shareholders participating in the Conference Call are typically allowed to ask 1 or 2 questions following the company's prepared statements.
To make the most of this Q&A opportunity with ELTP management, suggest that we come up with a list to share of top questions to ask:
(Copy/paste and add your question(s) at the end of the latest posted list)
1. Clinical Trials
a. When can we expect Lifetree abuse liability results?
b. How long do you expect these trials to last?
c. How many products are tested at a time in these studies?
d. Is the plan to file upon successful results?
2. Please explain the purpose for the upcoming meeting in October with the FDA. Best case and worst case scenario.
3. With so much going on will Analyst be reassess-updating last Falls value of Elite for future negotiations?
6. Lincoln Park Capital (LPC) Securities Funding
a. How many have been placed with LPC exclusive of the free shares?
b. How much money was generated for the shares?
c. How much of the money has been spent?
d. What was it used on?
7. 2 FDA applications ... what info can we get? How long have they been in the system?
8. 11 ANDA's for site transfer, what's going on?
9. Any plans for Eli-154?
10. What's the next step for Eli-201?
11. What's going on with the three drugs in Scale up?
12. Any generics moving up the ladder to commercialization?
13. Given the share price hovering at the “worst case” scenario, and far below the 2.10-2.75 levels that were indicated
as the more reasonable valuation range at that time, why are you comfortable with the valuation as reflective of Elite’s future?
14. In July, the FDA approved Purdue's Targiniq ER with labeling describing the product's abuse-deterrent properties. Is ELTP's ART more effective than Purdue's? If so, is it likely that the FDA will also approve ELTP's ART products?
**** Elite Pharmaceuticals Conference Call Questions ****
Shareholders participating in the Conference Call are typically allowed to ask 1 or 2 questions following the company's prepared statements.
To make the most of this Q&A opportunity with ELTP management, suggest that we come up with a list to share of top questions to ask:
(Copy/paste and add your question(s) at the end of the latest posted list)
1. Clinical Trials
a. When can we expect Lifetree abuse liability results?
b. How long do you expect these trials to last?
c. How many products are tested at a time in these studies?
d. Is the plan to file upon successful results?
2. Please explain the purpose for the upcoming meeting in October with the FDA. Best case and worst case scenario.
3. With so much going on will Analyst be reassess-updating last Falls value of Elite for future negotiations?
6. Lincoln Park Capital (LPC) Securities Funding
a. How many have been placed with LPC exclusive of the free shares?
b. How much money was generated for the shares?
c. How much of the money has been spent?
d. What was it used on?
7. 2 FDA applications ... what info can we get? How long have they been in the system?
8. 11 ANDA's for site transfer, what's going on?
9. Any plans for Eli-154?
10. What's the next step for Eli-201?
11. What's going on with the three drugs in Scale up?
12. Any generics moving up the ladder to commercialization?
13. Given the share price hovering at the “worst case” scenario, and far below the 2.10-2.75 levels that were indicated
as the more reasonable valuation range at that time, why are you comfortable with the valuation as reflective of Elite’s future?
13. In July, the FDA approved Purdue's Targiniq ER with labeling describing the product's abuse-deterrent properties. Is ELTP's ART more effective than Purdue's? If so, is it likely that the FDA will also approve ELTP's ART products?
ok, i'll remove that question from the list. Personally, i think it would have been better to reveal the name to protect ELTP from all the negativity dumped as a result of the secrecy on this point.